Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7257 in Severe Aplastic Anemia
NCT04409080Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1 trial of REGN7257 in aplastic anemia (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Adverse Events at 12 months, Serious Adverse Events at 78 weeks and 2 more. Started Jan 2021; status: terminated.
02
Drugs
REGN7257
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT04409080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409080.